LB1, a protein phosphatase 2A inhibitor, can reactivate dormant cancer cells by activating AKT and interfering with p53‐mediated cell cycle arrest, thereby sensitizing cells to cytotoxic agents. The gene discussed is AKT1; the disease is cancer.